Back to GetFilings.com
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2005
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from N/A to N/A
--- ---
Commission File No. 814-82
TECHNOLOGY FUNDING VENTURE PARTNERS V, AN AGGRESSIVE GROWTH FUND, L.P.
----------------------------------------------------------------------
(Exact name of Registrant as specified in its charter)
Delaware 94-3094910
- ------------------------------- ----------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
1107 Investment Blvd., Suite 180
El Dorado Hills, California 95762
- --------------------------------------- --------
(Address of principal executive offices) (Zip Code)
(916) 941-1400
-------------------------------
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act: Limited
Partnership Units
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes X No
--- ---
Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12B-2 of the Act). Yes No X
--- ---
No active market for the units of limited partnership interests ("Units")
exists, and therefore the market value of such Units cannot be determined.
Forward-Looking Statements
- --------------------------
The Private Securities Litigation Reform Act of 1995 (the Act) provides a
safe harbor for forward-looking statements made by or on behalf of the
Partnership. The Partnership and its representatives may from time to time
make written or oral statements that are "forward-looking," including
statements contained in this report and other filings with the Securities
and Exchange Commission, and reports to the Partnership's shareholders and
news releases. All statements that express expectations, estimates,
forecasts and projections are forward-looking statements within the meaning
of the Act. In addition, other written or oral statements, which
constitute forward-looking statements, may be made by or on behalf of the
Partnership. Words such as "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "projects," "forecasts," "may," "should,"
variations of such words and similar expressions are intended to identify
such forward-looking statements. These statements are not guarantees of
future performance and involve certain risks, uncertainties and
assumptions, which are difficult to predict. Therefore, actual outcomes
and results may differ materially from what is expressed or forecasted in
or suggested by such forward-looking statements. The Partnership
undertakes no obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or otherwise.
I. FINANCIAL INFORMATION
Item 1. Financial Statements
BALANCE SHEETS
- --------------
(unaudited)
March 31, December 31,
2005 2004
------------ ------------
ASSETS
Equity investments (cost of
$12,781,579 and $13,772,437 at
March 31, 2005, and December 31,
2004, respectively) $ 5,581,307 $6,597,470
Cash and cash equivalents 196,276 431,943
Prepaid expenses 179,855 199,547
Other assets 5,977 9,337
---------- ---------
Total assets $ 5,963,415 $7,238,297
========== =========
LIABILITIES AND PARTNERS' CAPITAL
Accounts payable and accrued expenses $ 1,074 $ 21,951
Due to related parties, net 22,264 50,383
Other liabilities 11,771 11,771
---------- ---------
Total liabilities 35,109 84,105
Commitments and contingencies (See Note 7)
Partners' capital
Limited Partners'
(400,000 units outstanding) 8,659,584 9,873,211
General Partners' (2,731,278) (2,719,019)
---------- ---------
5,928,306 7,154,192
---------- ---------
Total liabilities and partners' capital $ 5,963,415 $7,238,297
========== =========
See accompanying notes are an integral part of these financial statements.
STATEMENTS OF INVESTMENTS
- -------------------------
Principal
Amount or March 31, 2005 December 31, 2004
Industry Shares at ----------------- -----------------
(1) Investment March 31, Cost Fair Cost Fair
Company Position Date 2005 Basis Value Basis Value
- ---------------- -------- ---------- ----------- ----- ----- ----- -----
Equity Investments
- ------------------
Biomedical
- ----------
0.0% and 0.8% at March 31, 2005, and December 31, 2004, respectively
- --------------------------------------------------------------------
Celera Genomics Common
Group shares 2000 0 $ -- $ -- $ 141,000 $ 55,894
---------- --------- ---------- ---------
Biotechnology
- -------------
5.3% and 4.4% at March 31, 2005, and December 31, 2004, respectively
- --------------------------------------------------------------------
CellzDirect, Inc. Preferred 2002-
(a) (b) shares 2004 2,029,232 783,883 313,553 783,883 313,553
---------- --------- ---------- ---------
Communications
- --------------
0.0% and 2.4% at March 31, 2005, and December 31, 2004, respectively
- --------------------------------------------------------------------
iVillage Common
Inc. shares 2004 0 $ -- -- 152,401 169,950
---------- --------- ---------- ---------
Environmental
- -------------
0.0% and 0.0% at March 31, 2005, and December 31, 2004, respectively
- --------------------------------------------------------------------
Triangle Common
Biomedical shares and
Sciences, Inc.(a) attached
warrants at
$28.00;
expiring
2009 1999 1,806 37,366 0 37,366 0
---------- --------- ---------- ---------
High Tech/Financial
- -------------------
6.4% and 7.0% at March 31, 2005, and December 31, 2004, respectively
- --------------------------------------------------------------------
VenCore Solutions, 2002-
LLC (a) (b) LLC Units 2005 752,500 1,069,119 301,000 625,000 250,000
VenCore Solutions, 2002-
LLC (a)(b) various 2004 various 0 76,000 444,347 253,662
---------- --------- ---------- ---------
1,069,119 377,000 1,069,347 503,662
---------- --------- ---------- ---------
Industrial/Business Automation
- ------------------------------
11.1% and 10.7% at March 31, 2005, and December 31, 2004, respectively
- ---------------------------------------------------------------------
Innergy Power
Corporation Preferred 1995-
(a) (b) shares 2002 890,006 2,727,035 522,574 2,727,035 522,574
Various 1997-
investments various 2004 various 446,962 134,932 460,086 244,119
---------- --------- ---------- ---------
3,173,997 657,506 3,187,121 766,693
---------- --------- ---------- ---------
Information Technology
- ----------------------
7.1% and 5.9% at March 31, 2005, and December 31, 2004, respectively
- --------------------------------------------------------------------
KeyEye
Communications, Preferred 2002-
Inc. (a) (b) shares 2004 5,366,165 1,050,000 420,000 1,050,000 420,000
---------- --------- ---------- ---------
1,050,000 420,000 1,050,000 420,000
---------- --------- ---------- ---------
Medical
- -------
41.4% and 41.7% at March 31, 2005, and December 31, 2004, respectively
- ----------------------------------------------------------------------
Atherotech, Preferred 2000-
Inc. (a) (b) shares 2002 1,055,372 2,724,822 1,882,784 2,724,822 1,882,784
Impres Medical, Preferred 2002-
Inc.(a) (b) shares 2004 2,005,787 1,583,422 318,184 1,583,422 636,369
Various 1996-
investments various 2004 various 772,259 250,654 1,057,282 462,010
---------- --------- ---------- ---------
5,080,503 2,451,622 5,365,526 2,981,163
---------- --------- ---------- ---------
Retail/Consumer Products
- ------------------------
21.3% and 17.6% at March 31, 2005, and December 31, 2004, respectively
- --------------------------------------------------------------------
Dakota Arms, Preferred
Inc.(a) (b) shares 2004 571,430 1,000,001 1,000,003 1,000,001 1,000,003
Dakota Holdings, LLC
LLC (a) (b) units 2004 150,000 150,000 262,500 150,000 262,500
---------- --------- ---------- ---------
1,150,001 1,262,503 1,150,001 1,262,503
---------- --------- ---------- ---------
Venture Capital Limited Partnership Investments
- -----------------------------------------------
1.7% and 1.7% at March 31, 2005, and December 31, 2004, respectively
- --------------------------------------------------------------------
Various Ltd.
investments partnership
interests various various 436,710 99,123 835,792 124,052
---------- --------- ---------- ---------
Total investments - 94.15% and 92.2% at
March 31, 2005, and December 31, 2004,
respectively $12,781,579 $5,581,307 $13,772,437 $6,597,470
========== ========= ========== =========
Legend and footnotes:
- -- No investment held at end of period.
0 Investment active with a carrying value or fair value of zero.
(a) Equity security acquired in a private placement transaction; resale
may be subject to certain selling restrictions.
(b) Portfolio company is an affiliate of the Partnership; resale may be
subject to certain selling restrictions.
(1) Represents the total fair value of a particular industry segment as
a percentage of partners' capital at 03/31/05 and 12/31/04.
The accompanying notes are an integral part of these financial statements.
STATEMENTS OF OPERATIONS (unaudited)
- -----------------------------------
For the Three Months Ended March 31,
-----------------------------------
2005 2004
--------- ---------
Investment income:
Notes receivable interest $ 3,506 $ 12,319
Short-term interest income 115 6,804
------- -------
Total investment income 3,621 19,123
Investment expenses:
Management fees 20,191 25,866
Individual General Partners' compensation 15,000 10,625
Investment operations 101,840 219,955
Administrative and investor services 306,692 433,027
Professional fees 46,125 20,529
Computer services 32,148 29,554
Interest expense 28 7
------- -------
Total investment expenses 522,024 739,563
------- -------
Net investment loss (518,403) (720,440)
------- -------
Realized loss from venture capital
limited partnership write-offs (399,085) --
Net realized (loss) gain from sales
of equity investments (292,093) 243,510
Realized gain from venture capital
limited partnership investments 9,000 --
Realized gain from recovery of
investments previously written off -- 222,513
------- -------
Net realized (loss) gain income (682,178) 466,023
------- -------
(Increase) decrease in unrealized
depreciation:
Equity investments (25,305) 85,461
Notes receivable -- (645)
------- -------
Net (increase) decrease in
unrealized depreciation (25,305) 84,816
------- -------
STATEMENTS OF OPERATIONS (unaudited) (continued)
- -----------------------------------------------
Net decrease in partners'
capital resulting from operations $(1,225,886) $(169,601)
========= =======
Net decrease in partners'
capital resulting from operations
per Unit $ (3.03) $ (.42)
======= =======
See accompanying notes are an integral part of these financial statements.
STATEMENTS OF CASH FLOWS (unaudited)
- -----------------------------------
For the Three Months Ended March 31,
------------------------------------
2005 2004
--------- ---------
Net decrease in partners'
capital resulting from operations $(1,225,886) $ (169,601)
Adjustments to reconcile net
decrease in partners' capital
resulting from operations
to net cash used by operating
activities:
Net realized loss (gain) from sales
of equity investments 292,093 (243,510)
Realized gain from recovery of
investment previously written off -- (222,513)
Realized loss from venture capital
limited investment write offs 399,085 --
Realized gain from venture capital
limited partnership investments (9,000) --
Net increase (decrease) in unrealized
depreciation of equity investments 25,305 (85,461)
Net change in operating assets and
liabilities:
Unrealized depreciation of
notes receivable -- 645
Accrued interest on notes
receivable 13,348 (12,319)
Other receivables -- 117,486
Prepaid expenses 19,692 19,693
Accounts payable
and accrued expenses (20,877) (23,071)
Due to related parties, net (28,119) (773,214)
Other assets, net 3,360 5,649
--------- ---------
Net cash used by operating activities (530,999) (1,386,216)
--------- ---------
STATEMENTS OF CASH FLOWS (unaudited) (continued)
- -----------------------------------------------
Cash flows from investing activities:
Proceeds from sales of equity
investments 286,332 544,913
Purchase of equity investments -- (400,000)
Proceeds from venture capital
limited partnership investments 9,000 --
Proceeds from recovery of investments
previously written off -- 222,513
--------- ---------
Net cash provided by investing
activities 295,332 367,426
--------- ---------
Net decrease in cash and
cash equivalents (235,667) (1,018,790)
Cash and cash equivalents at
beginning of year 431,943 4,804,340
--------- ---------
Cash and cash equivalents
at March 31 $ 196,276 $3,785,550
========= =========
See accompanying notes are an integral part of these financial statements.
NOTES TO FINANCIAL STATEMENTS (unaudited)
- ----------------------------------------
1. Interim Financial Statements
----------------------------
The accompanying unaudited financial statements included herein have been
prepared in accordance with the requirements of Form 10-Q and, therefore,
do not include all information and footnotes, which would be presented,
were such financial statements prepared in accordance with generally
accepted accounting principles in the United States of America. These
statements should be read in conjunction with the Annual Report on Form 10-
K for the year ended December 31, 2004. In the opinion of the Managing
General Partners, the accompanying interim financial statements reflect all
adjustments necessary for the fair presentation of the financial position,
results of operations, and cash flows for the interim periods presented.
Allocation of income and loss to Limited and General Partners is based on
cumulative income and loss. Adjustments, if any, are reflected in the
current quarter balances. The results of operations for such interim
periods are not necessarily indicative of results of operations to be
expected for the full year or other interim periods.
2. Uncertain Future of the Partnership
-----------------------------------
The uncertainties arising from the timing of future liquidation events
raise substantial doubt about the Partnership's ability to continue as a
going concern. The accompanying interim financial statements do not
include any adjustments that might result from the outcome of these
uncertainties. As a result, the Independent General Partners have tasked
the Managing General Partners with examining a number of different options,
including the possible early sale of some of the Partnership's private
holdings.
3. Provision for Income Taxes
--------------------------
No provision for income taxes has been made by the Partnership, as the
Partnership is not directly subject to taxation. The partners are to
report their respective shares of Partnership income or loss on their
individual tax returns.
The accompanying financial statements are prepared using accounting
principles generally accepted in the United States of America, which may
not equate to tax basis accounting. The cost of investments on a tax basis
at March 31, 2005, and December 31, 2004, was $15,261,585 and $15,894,365,
respectively. At March 31, 2005, and December 31, 2004, gross unrealized
depreciation on investments based on cost for federal income tax purposes
was as follows:
March 31, December 31,
2005 2004
----------- -----------
Unrealized appreciation $ 220,043 $ 216,293
Unrealized depreciation (9,900,317) (9,513,188)
--------- ---------
Net unrealized depreciation $(9,680,274) $(9,296,895)
========= =========
4. Related Party Transactions
--------------------------
Related party costs are included in investment expenses shown on the
Statements of Operations. Related party costs for the three months ended
March 31, 2005 and 2004, were as follows:
2005 2004
-------- --------
Management fees $ 20,191 $ 25,866
Reimbursable operating expenses 516,145 409,843
Individual General Partners' compensation 15,000 10,625
The Partnership reimburses the Managing General Partners for certain
operating expenses incurred in connection with the business of the
Partnership. Reimbursable operating expenses paid by the Managing General
Partners include expenses (other than organizational and offering expenses
and general partner overhead) such as administrative and investor services,
investment operations, and computer services. Certain reimbursable
expenses have been accrued based upon interim estimates prepared by the
Managing General Partners and are adjusted to actual cost periodically.
There was $758,703 and $611,317 due to related parties and included in due
to related parties, net at March 31, 2005, and December 31, 2004,
respectively, for such reimbursable expenses.
Management fees due to the Managing General Partners were $6,730 and $3,597
at March 31, 2005, and December 31, 2004, respectively, which are included
in due to related parties.
Officers of the Managing General Partners occasionally receive stock
options as compensation for serving on the Boards of Directors of portfolio
companies. It is the Managing General Partners' policy that all such
compensation be transferred to the investing partnerships. If the options
are non-transferable, they are not recorded as an asset of the Partnership.
Any profit from the exercise of such options will be transferred if and
when the options are exercised and the underlying stock is sold by the
officers. Any such profit is allocated amongst the Partnership and
affiliated partnerships based upon their proportionate investments in the
portfolio company. At March 31, 2005, the Partnership and affiliated
partnerships had an indirect interest in non-transferable Sanarus Medical,
Inc. and Physiometrix, Inc. options with a fair value of $264.
Retention bonuses were offered to and accepted by key employees of the
Managing General Partners in late 2002. The bonuses, incremented by annual
salary increases, will be paid to those individuals who are still full-time
employees of the Managing General Partners in April 2007. The expense for
the bonus is recognized ratably over the beneficial period, October 2002 to
April 2007. As of March 31, 2005, the Partnership has recognized expense
of $177,243. Upon the resignation of personnel, no adjustment to the
retention bonus amount previously paid by the Partnership to the Managing
General Partners shall occur until a replacement person is hired.
As of March 31, 2005, and December 31, 2004, the Partnership has a due from
related party receivable of $743,169 and $557,337, respectively, related to
its investment in Dakota Holdings, LLC and Dakota Arms, Inc. The
Partnership has advanced funds to the company for operations. It is the
Managing General Partners' expectation that all or a portion of this
receivable will be converted into additional equity investments in Dakota
Holdings or otherwise paid in cash.
5. Equity Investments
------------------
All investments are valued at fair value as determined in good faith by the
Managing General Partners and in conjunction with Note 1 of the Form 10-K
for the year ended December 31, 2004.
Marketable Equity Securities
- ----------------------------
At March 31, 2005, and December 31, 2004, marketable equity securities had
aggregate costs of $374,717 and $953,141, respectively, and aggregate
market values of $180,326 and $507,913, respectively. The net unrealized
losses at March 31, 2005, and December 31, 2004, included gross gains of
$10,765 and $17,549, respectively.
Restricted Securities
- ---------------------
At March 31, 2005, and December 31, 2004, restricted securities had
aggregate costs of $12,406,862 and $12,819,296, respectively, and aggregate
fair values of $5,400,983 and $6,089,557, respectively, representing 91.1
percent and 84.1 percent, respectively, of the net assets of the
Partnership.
Significant purchases, sales and write-offs of equity investments during
the quarter ended March 31, 2005, are as follows:
Celera Genomics Group
- ---------------------
In March 2005, the Partnership sold its entire holdings in the company for
proceeds of $41,551 and recorded a realized loss of $99,449.
iVillage Inc.
- -------------
In March 2005, the Partnership sold its entire holdings in the company for
proceeds of $151,732 and recorded a realized loss of $669.
Physiometrix, Inc.
- -----------------
In March 2005, the Partnership sold its entire holdings in the company for
proceeds of $93,049 and recorded a loss of $191,975.
OW&W Pacrim Investments Limited
- -------------------------------
In March 2005, the Partnership received notice that the venture capital
limited partnership was terminating. The Partnership wrote off its entire
investment in the venture capital limited partnership and realized a loss
of $1,005.
Spectrum Equity Investors, L.P.
- -------------------------------
In March 2005, the Partnership wrote off its investment in the venture
capital limited partnership for a realized a loss of $398,080. The venture
capital limited partnership terminated at December 31, 2004. The
Partnership expects no return on its investment.
Vencore Solutions, LLC
- ----------------------
In January 2005, the company converted the Partnership's three notes
receivable, including accrued interest, for 127,500 Series A Units at a
cost of $444,124.
Other Equity Investments
- ------------------------
Other significant changes reflected in the Statements of Investments relate
to market value fluctuations for publicly traded portfolio companies or
changes in the fair value of private companies as determined in accordance
with the policy described in Note 1 to the financial statements included in
the Partnership's December 31, 2004, Form 10-K.
6. Cash and Cash Equivalents
-------------------------
Cash and cash equivalents at March 31, 2005, and December 31, 2004,
consisted of:
2005 2004
-------- --------
Demand accounts $195,688 $431,355
Money market accounts 588 588
--------- -------
Total $196,276 $431,943
========= =======
7. Commitments and Contingencies
-----------------------------
From time to time, the Partnership is a party to financial instruments with
off-balance-sheet risk in the normal course of its business. Generally,
these instruments are commitments for future equity fundings, venture
capital limited partnership investments, equipment financing commitments,
or accounts receivable lines of credit that are outstanding but not
currently fully utilized. As they do not represent current outstanding
balances, these unfunded commitments are not recognized in the financial
statements. At March 31, 2005, the Partnership had no unfunded equity
commitments.
From time to time, the Partnership is subject to routine litigation
incidental to the business of the Partnership. Although there can be no
assurances as to the ultimate disposition of these matters and the
commitments disclosed above, it is the opinion of the Managing General
Partners, based upon the information available at this time and advice from
legal counsel, that the expected outcome of these matters, individually or
in the aggregate, will not have a material adverse effect on the results of
operations and financial condition of the Partnership.
8. Financial Highlights
--------------------
For The Three Months Ended March 31,
-----------------------------------
2005 2004
------ ------
(all amounts on a per Unit basis)
Net asset value,
beginning of period $24.68 $33.37
Loss from investment
operations:
Net investment loss (1.28) (1.78)
Net realized and unrealized
(loss) gain on investments (1.75) 1.36
----- -----
Total from investment
operations (3.03) (0.42)
----- -----
Net asset value, end of period $21.65 $32.95
===== =====
Total return (12.29)% (1.26)%
Ratios to average net assets:
Net investment loss (5.54)% (5.38)%
Expenses 5.63% 5.30%
Pursuant to the Partnership Agreement, net profit shall be allocated first
to those Partners with deficit capital account balances until such deficits
have been eliminated. The net asset values shown above assume the
Partnership is in liquidation. Upon liquidation, the General Partners
would contribute capital equal to the amount of the General Partners'
deficit. As of March 31, 2005 and December 31, 2004, the General Partners
had a negative capital balance of $2,731,278 and $2,719,019, respectively.
Net asset value has been calculated in accordance with the provisions of
the Partnership Agreement.
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations
Liquidity and Capital Resources
- -------------------------------
The Partnership operates as a business development company under the
Investment Company Act of 1940 and makes venture capital investments in new
and developing companies. The Partnership's financial condition is
dependent upon the success of the portfolio companies. There is no ready
market for many of the Partnership's investments. It is possible that some
of its venture capital investments may be a complete loss or may be
unprofitable and that others will appear likely to become successful, but
may never realize their potential. The valuation of the Partnership's
investments in securities for which there are no available market quotes is
subject to the estimate of the Managing General Partners in accordance with
the valuation guidance described in Note 1 to the financial statements
included in the Partnership's December 31, 2004, Form 10-K. In the absence
of readily obtainable market values, the estimated fair value of the
Partnership's investments may differ significantly from the values that
would have been used had a ready market existed.
The Partnership continues to experience decreases in partners' capital
resulting from overall market declines and from operations. For the three
months ended March 31, 2005, the Partnership incurred a net decrease in
partners' capital of $1,225,886. In addition, the Partnership's liquid
assets, including unrestricted marketable equity investments, are not
adequate to fund ongoing operations of the Partnership for 2005. These
factors, among others, raise substantial doubt about the Partnership's
ability to continue as a going concern. As a result, the Independent
General Partners have tasked the Managing General Partners with examining a
number of different options, including the possible early sale of some of
the Partnership's private holdings. The accompanying financial statements
do not include any adjustments that might result from the outcome of these
uncertainties.
During the three months ended March 31, 2005, net cash used by operating
activities totaled $530,999. The Partnership paid management fees of
$9,864 to the Managing General Partners and reimbursed related parties for
other investment expenses of $494,937. In addition, $15,000 was paid to
the Individual General Partners as compensation for their services. The
Partnership paid other investment expenses of $28,127. The Partnership
received interest income of $16,929.
During the three months ended March 31, 2005, the Partnership funded no
equity investments. At March 31, 2005, the Partnership had no commitments
to fund additional investments.
Results of Operations
- ---------------------
Current quarter compared to corresponding quarter in the preceding year
- -----------------------------------------------------------------------
Net decrease in partners' capital resulting from operations was $1,225,886
for the three months ended March 31, 2005, compared to a net decrease in
partners' capital resulting from operations of $169,601 for the same period
in 2004.
During the quarter ended March 31, 2005, there were two venture capital
limited partnership investment write-offs totaling $399,085. In March
2004, there were no write-offs.
Net unrealized depreciation on equity investments was $7,200,272 and
$7,174,967 at March 31, 2005, and December 31, 2004, respectively. During
the quarter ended March 31, 2005, the Partnership recorded an increase in
net unrealized depreciation on equity investments of $25,305, compared to a
decrease in unrealized depreciation of $85,461 during 2004. The increase
in depreciation in 2005 was primarily attributable to write-offs of two
venture capital limited partnership investments. The change in 2004 was
primarily attributable to the publicly traded price of Acusphere, Inc.
Total investment expenses were $522,024 for the quarter ended March 31,
2005, compared to $739,563 for the same period in 2004. The decrease was
primarily due to decreased administrative and investor monitoring, which
was partially offset by increased professional fees and computer service
costs.
There was no net unrealized depreciation on notes receivable at March 31,
2005, and December 31, 2004, respectively. During the quarter ended March
31, 2005, there was no unrealized depreciation of notes receivable. During
the same period in 2004, the Partnership recorded an increase in unrealized
depreciation of $645.
Given the inherent risk associated with the business of the Partnership,
the future performance of the portfolio company investments may
significantly impact future operations.
Item 4. Controls and Procedures
The undersigned is responsible for establishing and maintaining disclosure
controls and procedures for Technology Funding Venture Partners V, An
Aggressive Growth Fund, L.P. Such officer has concluded (based upon his
evaluation of these controls and procedures as of a date within 90 days of
the filing of this report) that Technology Funding Venture Partners V, An
Aggressive Growth Fund, L.P.'s disclosure controls and procedures are
effective to ensure that information required to be disclosed by Technology
Funding Venture Partners V, An Aggressive Growth Fund, L.P. in this report
is accumulated and communicated to Technology Funding Venture Partners V,
An Aggressive Growth Fund, L.P.'s management, including its principal
executive officers as appropriate, to allow timely decisions regarding
required disclosure.
The certifying officer also has indicated that there were no significant
changes in Technology Funding Venture Partners V, An Aggressive Growth
Fund, L.P.'s internal controls or other factors that could significantly
affect such controls subsequent to the date of their evaluation other than
changes needed to maintain adequate separation of duties and
responsibilities of personnel in the ordinary course of business, and there
were no corrective actions with regard to significant deficiencies and
material weaknesses.
SIGNATURES
----------
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be
signed on its behalf by the undersigned, thereunto duly authorized.
TECHNOLOGY FUNDING VENTURE PARTNERS V,
AN AGGRESSIVE GROWTH FUND, L.P.
By: TECHNOLOGY FUNDING INC.
TECHNOLOGY FUNDING LTD.
Managing General Partners
Date: May 12, 2005 By: /s/Charles R. Kokesh
---------------------
Charles R. Kokesh
President, Chief Executive Officer,
Chief Financial Officer and
Chairman of Technology Funding Inc.
and Managing General Partner of
Technology Funding Ltd.
Technology Funding Venture Partners V, An Aggressive Growth Fund, L.P.
(a Delaware limited partnership) 5/11/2005 5:22 PM
Page 8 of 22